Abstract | OBJECTIVE: MATERIALS AND METHODS: RESULTS: HT-1376 cells expressed P2X(4,5,7) and P2Y(1,2,4,6,11) receptor mRNA. ATP significantly reduced cell growth in a concentration-dependent manner via the induction of P2 receptor-mediated apoptosis. Pharmacological profiling implicated P2X(5) and/or P2Y(11) receptors in this antineoplastic response, the same receptor subtypes shown to be active in prostate adenocarcinoma, despite the differing cellular origin. ATP and MMC combined in an additive manner. Intraperitoneal injections of ATP significantly reduced the growth of implanted tumour cells by a combination of apoptosis and necrosis. CONCLUSIONS:
ATP effectively reduces the growth of high-grade bladder cancer cells in vitro and in vivo. This highlights the potential use of ATP in the treatment of advanced urological malignancies irrespective of the cellular origin.
|
Authors | Majid Shabbir, Mina Ryten, Cecil Thompson, Dimitri Mikhailidis, Geoffrey Burnstock |
Journal | BJU international
(BJU Int)
Vol. 101
Issue 1
Pg. 106-12
(Jan 2008)
ISSN: 1464-410X [Electronic] England |
PMID | 17941929
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Receptors, Purinergic P2
- Adenosine Triphosphate
|
Topics |
- Adenosine Triphosphate
(pharmacology)
- Animals
- Antineoplastic Agents
(pharmacology)
- Carcinoma, Transitional Cell
(drug therapy, pathology)
- Cell Line, Tumor
- Female
- Humans
- Male
- Mice
- Mice, Nude
- Middle Aged
- Receptors, Purinergic P2
(drug effects)
- Reverse Transcriptase Polymerase Chain Reaction
- Risk Factors
- Signal Transduction
- Urinary Bladder Neoplasms
(drug therapy, pathology)
|